Top Swedish Growth Companies With High Insider Ownership August 2024
Reviewed by Simply Wall St
As global markets experience heightened volatility and economic uncertainties, the Swedish market has shown resilience, with certain growth companies standing out due to their robust insider ownership. In this context, high insider ownership can be a positive indicator of confidence in a company's future prospects, making it an essential factor for investors to consider.
Top 10 Growth Companies With High Insider Ownership In Sweden
Name | Insider Ownership | Earnings Growth |
CTT Systems (OM:CTT) | 16.9% | 24.8% |
Magle Chemoswed Holding (OM:MAGLE) | 14.9% | 72.2% |
Biovica International (OM:BIOVIC B) | 18.7% | 73.8% |
Yubico (OM:YUBICO) | 37.5% | 43.8% |
InCoax Networks (OM:INCOAX) | 18.1% | 104.9% |
BioArctic (OM:BIOA B) | 34% | 104.2% |
KebNi (OM:KEBNI B) | 37.8% | 90.4% |
Calliditas Therapeutics (OM:CALTX) | 11.6% | 52.9% |
SaveLend Group (OM:YIELD) | 23.3% | 103.4% |
edyoutec (NGM:EDYOU) | 13.4% | 63.1% |
Let's take a closer look at a couple of our picks from the screened companies.
BioArctic (OM:BIOA B)
Simply Wall St Growth Rating: ★★★★★★
Overview: BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden and has a market cap of SEK14.35 billion.
Operations: BioArctic's revenue primarily comes from its biotechnology segment, which generated SEK252.21 million.
Insider Ownership: 34%
BioArctic, a Swedish biotech firm with significant insider ownership, has recently seen its Alzheimer's drug Leqembi approved in Hong Kong. This follows approvals in the US, Japan, China, and South Korea. Despite a volatile share price and recent financial losses (SEK 57.56 million net loss in Q1 2024), analysts forecast robust revenue growth of 39.1% annually and profitability within three years. Insider transactions have been more buys than sells recently, indicating confidence from within the company.
- Delve into the full analysis future growth report here for a deeper understanding of BioArctic.
- Our comprehensive valuation report raises the possibility that BioArctic is priced lower than what may be justified by its financials.
Haypp Group (OM:HAYPP)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Haypp Group AB (publ) is an online retailer specializing in tobacco-free nicotine pouches and snus products across Sweden, Norway, the rest of Europe, and the United States, with a market cap of SEK2.96 billion.
Operations: Revenue segments for the company include Core at SEK2.42 billion and Growth at SEK834.20 million.
Insider Ownership: 10.9%
Haypp Group, with substantial insider ownership, is poised for significant earnings growth of 88.6% per year, outpacing the Swedish market's 15.7%. Despite a slight dip in profit margins from 0.8% to 0.5%, revenue is expected to grow at 16.5% annually, faster than the market average of 1.1%. Recent board additions include Deppak Mishra and Adam Schatz as of May 2024, potentially strengthening governance amid this growth trajectory.
- Click here and access our complete growth analysis report to understand the dynamics of Haypp Group.
- In light of our recent valuation report, it seems possible that Haypp Group is trading beyond its estimated value.
Scandi Standard (OM:SCST)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Scandi Standard AB (publ) produces and sells chilled, frozen, and ready-to-eat chicken products across various countries including Sweden, Norway, Ireland, Denmark, Finland, Germany, the United Kingdom, and internationally; it has a market cap of SEK5.48 billion.
Operations: Revenue segments are divided into Ready-To-Eat products generating SEK2.61 billion and Ready-To-Cook products contributing SEK9.70 billion.
Insider Ownership: 14.6%
Scandi Standard, with substantial insider buying over the past three months, is forecast to see earnings grow significantly at 20.4% per year, outpacing the Swedish market's 15.7%. Despite a high debt level and an unstable dividend track record, it trades at 48.2% below its estimated fair value. Recent developments include securing a SEK 3,200 million sustainability-linked bank loan to refinance existing debt and support growth ambitions.
- Dive into the specifics of Scandi Standard here with our thorough growth forecast report.
- Insights from our recent valuation report point to the potential undervaluation of Scandi Standard shares in the market.
Summing It All Up
- Unlock our comprehensive list of 88 Fast Growing Swedish Companies With High Insider Ownership by clicking here.
- Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
- Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.
Curious About Other Options?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're here to simplify it.
Discover if BioArctic might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About OM:BIOA B
BioArctic
Develops biological drugs for patients with disorders of the central nervous system in Sweden.
Exceptional growth potential with flawless balance sheet.